
Sting-Activating Gm-Csf Secreting Allogeneic Pancreas Tumor Cell Vaccine TherapyAward last edited on: 10/28/14
Sponsored Program
SBIRAwarding Agency
NIH : NCITotal Award Amount
$224,878Award Phase
1Solicitation Topic Code
-----Principal Investigator
Thomas W Dubensky JrCompany Information
Aduro BioTech Inc (AKA: Nanotx Corporation~Oncologic Inc)
626 Bancroft Way Suite 3c
Berkeley, CA 94710
Berkeley, CA 94710
(510) 848-4400 |
bd@adurobiotech.com |
www.adurobiotech.com |
Location: Single
Congr. District: 12
County: Alameda
Congr. District: 12
County: Alameda
Phase I
Contract Number: 1R43CA186424-01Start Date: 9/10/14 Completed: 9/9/15
Phase I year
2014Phase I Amount
$224,878Thesaurus Terms:
Abraxane;Adjuvant;Allogenic;Allogenic Cell Vaccine;Applications Grants;Attenuated;Base;Biological;Biological Assay;Cancer Immunotherapy;Cancer Vaccines;Cd8b1 Gene;Cell Bank;Cell Differentiation Process;Cell Line;Cell Maturation;Cells;Chemotherapy-Oncologic Procedure;Clinical;Clinical Research;Clinical Trials;Collaborations;Coupled;Critical Pathways;Cyclophosphamide;Data;Dendritic Cell Activation;Dendritic Cells;Design;Development;Diagnosis;Dinucleoside Phosphates;Disease;Disease-Free Survival;Dosage;Dose;Drug Formulations;Effectiveness;Evaluation;Genes;Goals;Granulocyte-Macrophage Colony-Stimulating Factor;Human;Immune;Immune System;Immunity;Immunogenicity;Immunologics;Immunotherapeutic Agent;Immunotherapy;Improved;Incidence;Individual;Injection Of Therapeutic Agent;Inorganic Phosphate;Intellectual Property;Interferons;Lead;Life;Listeria Monocytogenes;Malignant Neoplasm Of Pancreas;Malignant Neoplasms;Measures;Mediator Of Activation Protein;Mesothelin;Mortality Vital Statistics;Mus;Natural Immunity;Nature;Neoplastic Cell;Novel;Novel Strategies;Novel Therapeutics;Oryctolagus Cuniculus;Outcome;Pancreas;Pancreas Development;Pancreatic Adenocarcinoma;Pancreatic Ductal Adenocarcinoma;Pancreatic Neoplasm;Pathogen;Patients;Pharmacology And Toxicology;Phase;Phase Ii Clinical Trials;Phosphoric Diester Hydrolase;Pre-Clinical;Public Health Relevance;Publishing;Randomized;Receptor;Recombinants;Recruitment Activity;Regimen;Resected;Resistance;Response;Safety;Sentinel;Signaling Pathway Gene;Site;Small Business Innovation Research Grant;Small Molecule;Staging;Stimulus;Success;T Cell Response;T-Lymphocyte;Testing;Therapeutic;Therapeutic Vaccine;Toxic Effect;Toxicology;Treatment Efficacy;Treatment Factor;Treatment Strategy;Tumor;Tumor Antigens;Universities;Unresectable;Vaccine Therapy;Vaccines;Whole Cell Vaccine;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00